TafluposideAlternative Names: F 11782
Latest Information Update: 09 Nov 2007
At a glance
- Originator Pierre Fabre
- Class Antineoplastics
- Mechanism of Action DNA topoisomerase I inhibitors; DNA topoisomerase inhibitors; Type II DNA topoisomerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 09 Nov 2007 Data presented at the 19th AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2007) added to the adverse events and Cancer therapeutic trials sections
- 06 Aug 2007 This compound is still undergoing active development
- 06 Aug 2005 Phase-I clinical trials in Solid tumours in France (IV)